PATIENTS receiving modern B-cell-depleting therapies face a heightened risk of severe arboviral disease with substantial mortality. A clinical safety alert underscores severe, atypical, and life-threatening neuroinvasive infections among patients undergoing therapy with anti-CD20 monoclonal antibodies, such as rituximab, anti-CD38 agents, and BAFF inhibitors. Published observational evidence indicates that individuals on these immunosuppressive regimens experience mortality rates approaching forty percent following neuroinvasive arboviral infections, with surviving individuals frequently suffering persistent, debilitating neurological deficits.
The primary causative pathogen identified across clinical reports is West Nile virus, alongside Powassan virus, Eastern equine encephalitis, and orthobunyaviruses such as Jamestown Canyon and Cache Valley viruses. In contrast to immunocompetent populations where viral exposure often yields asymptomatic seroconversion or self-limiting febrile illness, patients on targeted immunosuppression can develop aggressive, chronic neurodegenerative encephalitis. Furthermore, these atypical presentations may progress insidiously over several months or years rather than presenting acutely, confounding standard clinical timelines. Practitioners must maintain a high index of suspicion outside traditional summer and autumn transmission windows, as impaired viral clearance leads to protracted incubation periods and persistent viremia.
Standard serologic evaluation poses a major diagnostic challenge in this patient population. Because B-cell depletion blunts humoral immune responses and antibody synthesis, conventional IgM and IgG enzyme immunoassays regularly yield false-negative results. Clinicians assessing suspected severe arboviral disease in immunocompromised hosts must not rely on negative serology to rule out infection. Instead, expert guidelines mandate immediate molecular testing via reverse transcription polymerase chain reaction or metagenomic next-generation sequencing on cerebrospinal fluid, plasma, serum, or biopsy tissue to confirm active viral replication in patients treated for rheumatologic diseases or hematologic malignancies.
Because effective, targeted antiviral treatments for arboviruses remain unavailable, proactive pre-treatment counseling and rigorous vector prevention serve as the primary defensive line. Healthcare providers managing patients on B-cell-depleting therapies should emphasize comprehensive personal protective measures, including the consistent use of EPA-registered insect repellents, application of permethrin-treated clothing, and avoidance of mosquito and tick habitats during peak exposure times.
Reference
Centers for Disease Control and Prevention. Risk of Severe Arboviral Disease in Patients Receiving B Cell-Depleting or Modulating Medications. CDC Health Alert Network. 2026;CDCHAN-00516.
Featured Image: Love You Stock on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
